EGFR and non-small cell lung carcinoma: To understand the efficacy of afatinib for patients with advanced NSCLC carrying uncommon EGFR mutations, a pooled analysis of phase two trials (LUX-Lung2) and randomized phase three trials (LUX-Lung3 and LUX-Lung6) showed that individuals with major uncommon mutations, such as G719X, L861Q, or S768I, had substantially longer medians for PFS and OS than those with other uncommon EGFR mutations.